Lexeo Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 12, 2026

LXEO$3.06-2.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Stockholders’ Equity (unaudited)

Condensed Statements of Stockholders’ Equity

(Unaudited, in thousands, except share amounts)

Accumulated
Additional · Other · Total
Common Stock · Treasury · Paid-in · Comprehensive · Accumulated · Stockholders'
	Shares	Amount	Stock	Capital	Income (Loss)	Deficit	Equity
Balances at December 31, 2025	73,001,350	$7	$(17)	$626,625	$188	$(380,134)	$246,669
Issuance of common stock upon vesting and settlement of restricted stock units	163,310	-	-	-	-	-	-
Issuance of common stock under 2023 ESPP	52,285	-	-	143	-	-	143
Issuance of common stock upon exercise of common warrants	867,302	-	-	2,446	-	-	2,446
Exercise of stock options	2,400	-	-	9	-	-	9
Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase	90	-	-	1	-	-	1
Unrealized comprehensive loss on investments in U.S. Treasury securities	-	-	-	-	(330)	-	(330)
Stock-based compensation expense	-	-	-	2,755	-	-	2,755
Net loss	-	-	-	-	-	(20,196)	(20,196)
Balances at March 31, 2026	74,086,737	$7	$(17)	$631,979	$(142)	$(400,330)	$231,497
Issuance of common stock related to ATM Program, net of fees and offering costs of $1,424	4,424,778	1	-	23,575	-	-	23,576
Issuance of common stock upon vesting and settlement of restricted stock units	47,211	-	-	-	-	-	-
Exercise of stock options	63,818	-	-	320	-	-	320
Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase	60	-	-	1	-	-	1
Unrealized comprehensive loss on investments in U.S. Treasury securities	-	-	-	-	(156)	-	(156)
Stock-based compensation expense	-	-	-	5,690	-	-	5,690
Net loss	-	-	-	-	-	(25,867)	(25,867)
Balances at June 30, 2026	78,622,604	$8	$(17)	$661,565	$(298)	$(426,197)	$235,061

Accumulated
Additional · Other · Total
Common Stock · Treasury · Paid-in · Comprehensive · Accumulated · Stockholders'
	Shares	Amount	Stock	Capital	Income (Loss)	Deficit	Equity
Balances at December 31, 2024	33,071,261	$3	$(17)	$397,132	$(103)	$(280,173)	$116,842
Issuance of common stock upon vesting and settlement of restricted stock units	52,446	-	-	-	-	-	-
Issuance of common stock under 2023 ESPP	65,342	-	-	170	-	-	170
Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase	2,816	-	-	13	-	-	13
Unrealized comprehensive gain on investments in U.S. Treasury securities	-	-	-	-	49	-	49
Stock-based compensation expense	-	-	-	3,697	-	-	3,697
Net loss	-	-	-	-	-	(32,656)	(32,656)
Balances at March 31, 2025	33,191,865	$3	$(17)	$401,012	$(54)	$(312,829)	$88,115
Issuance of common stock upon vesting and settlement of restricted stock units	14,097	-	-	-	-	-	-
Issuance of common stock, pre-funded warrants and warrants to purchase common stock upon May 2025 Private Placement Offering, net of commissions and offering costs of $6,917	20,790,120	2	-	73,080	-	-	73,082
Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase	2,410	-	-	12	-	-	12
Unrealized comprehensive gain on investments in U.S. Treasury securities	-	-	-	-	41	-	41
Stock-based compensation expense	-	-	-	3,071	-	-	3,071
Net loss	-	-	-	-	-	(26,103)	(26,103)
Balances at June 30, 2025	53,998,492	$5	$(17)	$477,175	$(13)	$(338,932)	$138,218

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.